Evidence map›Paper›PMID 20933030›Full record

ArticlePeptides2011

Central nesfatin-1 reduces the nocturnal food intake in mice by reducing meal size and increasing inter-meal intervals.

Miriam Goebel, Andreas Stengel, Lixin Wang, Yvette Taché

Abstract read
In one paragraph

Article in Peptides, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 115 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Role of the gut-brain axis in energy and glucose metabolism.Experimental & molecular medicine · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Nesfatin-1 decreases the motivational and rewarding value of food.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Article
  11. Article
  12. Article
  13. Current Understanding of the Role of Nesfatin-1.Journal of the Endocrine Society · 2018
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Miriam GoebelCURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and Veterans Affairs Greater Los Angeles Health Care System, CA 90073, USA.
Andreas Stengel
Lixin Wang
Yvette Taché
University of California, Los Angeles · USVA Greater Los Angeles Healthcare System · US

Funding

Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
CORTICOTROPIN-RELEASING FACTOR--BIOLOGICAL ACTIONR01DK033061 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TACHE, YVETTE FRANCE · 1986 to 2012
$2.5M
CORTICOTROPIN-RELEASING FACTOR-ACTION ON GI FUNCTIONR37DK033061 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TACHE, YVETTE FRANCE · 1995 to 2002
$869k
NIDDK NIH HHS DK-41301NIDDK NIH HHS P30 DK041301NIDDK NIH HHS R01 DK033061NIDDK NIH HHS R01 DK-33061NIDDK NIH HHS R37 DK033061
6 · The paper itself

Abstract

Nesfatin-1 is well established to reduce food intake upon brain injection in rats, while in mice its anorexigenic action and brain expression are largely unexplored. We characterized the influence of intracerebroventricular (icv) and peripheral (intraperitoneal, ip, subcutaneous, sc) injection of nesfatin-1 on dark phase ingestive behavior using an automated feeding monitoring system and co-localized NUCB2/nesfatin-1 immunoreactivity in the associated brain areas. Nesfatin-1 (0.3, 1 or 3 μg/mouse, icv) caused a dose-related reduction of 4-h dark phase food intake by 13%, 27%, and 46% respectively. Nesfatin-1 (3 μg/mouse, icv) action had a 2-h delayed onset, 82% peak inhibition occurring at 3-4h post-injection and was long lasting (30% reduction for 12h period post-injection). Nesfatin-1 (3 μg/mouse, icv)-treated mice had a 46% lower meal frequency associated with 2-times longer inter-meal intervals and a 35% reduction in meal size compared to vehicle during the 1-4h post-injection (p<0.05). NUCB2/nesfatin-1-immunopositive neurons were found in hypothalamic (supraoptic, paraventricular, arcuate, dorsomedial, lateral) and brainstem (dorsal vagal complex) feeding regulatory nuclei. When injected peripherally, neither food intake nor feeding microstructure parameters were altered. These results demonstrate that NUCB2/nesfatin-1 is prominently expressed in mouse hypothalamus and medulla and acts in the brain to curtail the dark phase feeding by inducing satiation and satiety indicated by reduced meal size and prolonged inter-meal intervals respectively. The lack of nesfatin-1 effect when injected peripherally at a 23-times higher dose indicates a primarily central site of the anorexigenic action for nesfatin-1 in mice.

Indexed as

AnimalsCalcium-Binding ProteinsDNA-Binding ProteinsEatingFeeding BehaviorInjections, IntraventricularMaleMiceMice, Inbred BALB CNerve Tissue ProteinsNeuronsNucleobindinsCalcium-Binding ProteinsDNA-Binding ProteinsNerve Tissue ProteinsNucb1 protein, mouseNucb1 protein, ratNucleobindins

Identifiers

PMID20933030
PMCPMC3010516
OpenAlexW2064081737

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.